VPATAPP Exclusive_Free** patent equivalent service launched in New version of VPATAPP

VPATAPP is pleased to announce VPAT-Eq™, a first of it's kind patent equivalent search service. Especially designed for the IPR teams, this service provides a low cost option of identifying the patent equivalents. 

Features of the service:

Services included	Fees
Initial subscription	Zero
Patent equivalent searches upto 20 per month
If equivalent is not identified	Zero
If equivalent is identified	Fixed cost in 4 digits.....
Patent equivalent searches beyond 20 to 50 per month
If equivalent is not identified	500 Rs. Per search
If equivalent is identified	Fixed cost in 4 digits.....
Patent equivalent searches beyond 51 onwards per month
If equivalent is not identified	1000 Rs. Per search
If equivalent is identified	Fixed cost in 4 digits.....

How to utilize the service:

1. Download "VPATAPP", available freely on Android and iOS.

2. Go to the VPAT-Eq tab.

3. Include any patent number you have. e.g. US5678901

4. Select the country for which you require the patent equivalent from the drop-down menu.

5. Get a client code (After CDA and service agreement) from us. This is a one time activity.

6. Include your email address in the request.

7. Within 7 working days, you would receive the report for the same.

How is the method unique?

1. The client need not pay (as per above table) if we couldn't identify the equivalent. 

2. The service is not a legal opinion, but the equivalents are identified by the experts and not by any automated service.
3. The service is available for countries included in the app.
4. No minimum number of searches required to continue the subscription.
5. Invoices in rupees and not in Euros or Dollars.
6. No initial subscription charge for the service. 
7. Value added services like legal status; claims; full text patents and translation at extra cost.
8. 24*7 online service to send the equivalent via the app.
9. No hidden costs beyond the fixed cost as defined in MOU. 

VPATAPP Alert_As Niche Patent Practice Area Ramps Up, Big Law Firms Jump In

https://biglawbusiness.com/as-niche-patent-practice-area-ramps-up-big-law-firms-jump-in/

New practice area evolves as more than 7,900 patent validity challenges filed at patent office since September 2012

U.S. Supreme Court will rule on constitutionality of the proceedings, attorneys aren’t worried

Big law firms have ramped up to handle an evolving new patent practice area: patent validity challenges that have quickly become the battleground for an increasing number of multi-billion dollar disputes.

More and more intellectual property law attorneys now practice before the Patent Trial and Appeal Board (PTAB), a patent office tribunal created by a 2011 law as a fast-track and less expensive alternative to patent validity challenges in federal district courts.

VPATAPP Alert_Litigation Funding in Brazil Could Explode After 231,000 Patents Are Granted to Reduce Backlog

https://litigationfinancejournal.com/litigation-funding-brazil-explode-231000patents-granted-reduce-backlog/

For the past 15 years, Brazil has suffered one of the world’s most chronic and severe backlogs of pending patents. Now, the Brazilian Patent and Trademark Office (PTO), is looking to reduce that backlog in one fell swoop: by granting patent rights until 2020 to 231,000 pending applications with no examination.

This however does not include pharma patents.

VPATAPP Alert_Golden Disclaimers in Europe

http://www.mondaq.com/x/662522/Patent/Golden+Disclaimers

Article by Christian Köster

Dennemeyer Group

The Enlarged Board of Appeal of the European Patent Office has issued decision G 1/16 on the allowability of undisclosed disclaimers introduced into a patent claim. This decision confirms that "undisclosed disclaimers" in European patent applications are permissible under certain circumstances thus clarifying a decade-old saga on this matter.

VPATAPP Alert_Patent Portfolio Management - a Team Approach to Patent Drafting

https://www.lexology.com/library/detail.aspx?g=6dda4847-5b1f-420f-87e6-f7d54b669529

By Baker & Hostetler LLP.

VPATAPP Alert_The Impact of Coming Changes in European Union Patent Litigation on U.S. Patent Owners’ Enforcement Strategies

https://www.lexology.com/library/detail.aspx?g=3e113fcc-0779-4752-b730-88e6db1f9899

For some savvy patent owners, enforcing patent rights through European Union (EU) courts has been a valuable tool in their efforts to extract value from their patent portfolios, whether those strategies focus on market exclusivity or monetization. The reasons include significant cost savings in comparison to U.S. litigation, the relative speed of certain EU jurisdictions and the perception that certain of the EU courts are decidedly patent friendly.

By Vorys Sater Seymour and Pease LLP

VPATAPP Alert_2017 Patent Year In Review

https://abovethelaw.com/2018/01/2017-patent-year-in-review/

Update from the USA: What were some of the most important things to happen in the patent (or patent-related) world in 2017?

By By Krista L. Cox

·       Confusion over USPTO leadership

·       Allergan pays Native American tribe to exploit sovereign immunity.

·       SCOTUS applies international exhaustion of patent rights.

·       SCOTUS changes venue rules.

·       Shake-up in the House Judiciary Committee Leadership.

VPATAPP Alert_Federal Biosimilars Act Preempts State Law

https://www.lexology.com/library/detail.aspx?g=97fc0519-92e8-4dcf-ab0e-64cf91dbe585

By Rothwell, Figg, Ernst & Manbeck, PC.

On December 14, 2017, the Federal Circuit issued an opinion in Amgen v. Sandoz, holding that the Biologics Price Competition and Innovation Act of 2009 (“BPCIA,” the “Act”) preempts state law, and thus state laws cannot be used to enforce participation in the BPCIA’s patent dispute resolution procedures and disclosure process. In light of the Supreme Court’s holding earlier this year that such participation is not enforceable by an injunction under federal law and that biosimilar applicants need not wait for approval from the U.S. Food and Drug Administration (“FDA”) before providing the statutorily required notice of commercial marketing, this case is a major win for biosimilar applicants and manufacturers alike.